Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706679 · ClinicalTrials.gov registry record · Phase 1
Evaluation of the Effect of ATX-101 on QT/QTc Intervals
A Phase 1 study, sponsored by Kythera Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 218
- Enrollment target
NCT01706679 is a Phase 1 study that has completed, run by Kythera Biopharmaceuticals. The registered enrollment target is 218 participants.
The verdict
NCT01706679, a Phase 1 study, has completed, sponsored by Kythera Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 218 participants
- Enrollment target
Study Summary
To evaluate the effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF).
Interventions
- DRUG ATX-101 (10 mg/ml)
- DRUG ATX-101 (20 mg/ml)
- DRUG Moxifloxacin (400 mg)
- DRUG Placebo vehicle (PBS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2012-10 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01706679
The ClinicalTrials.gov registry entry for NCT01706679 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kythera Biopharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which ATX-101 (10 mg/ml) is the first listed.
NCT01706679 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01706679 about?
NCT01706679 is a clinical study titled "Evaluation of the Effect of ATX-101 on QT/QTc Intervals". To evaluate the effect of maximum therapeutic and supratherapeutic doses of ATX-101 treatment on Fridericia's corrected QT interval (QTcF).
What is the current status of trial NCT01706679?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 218 participants. The study started on 2012-10. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01706679?
The interventions under investigation include: ATX-101 (10 mg/ml) (DRUG), ATX-101 (20 mg/ml) (DRUG), Moxifloxacin (400 mg) (DRUG), Placebo vehicle (PBS) (DRUG).
Who is sponsoring clinical trial NCT01706679?
This trial is sponsored by Kythera Biopharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.